Graves Disease: Multimedia

References

1. Lavard L, Ranlov I, Perrild H, et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol. Jun 1994;130(6):565-8. [Medline].

2. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm. Accessed June 3, 2009.

3. Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves's patients. J Clin Endocrinol Metab. 2004;89:4229-4233. [Medline]. [Full Text].

4. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-85. [Medline].

5. Beck-Peccoz P, Persani L, LaFranchi S. Safety of medications and hormones used in the treatment of pediatric thyroid disorders. Pediatr Endocrinol Rev. 2004;2:124-133. [Medline].

6. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:398-409. [Medline].

7. Cassio A, Corrias A, Gualandi S, et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: results of a collaborative study. Clin Endocrinol (Oxf). 2006;64:53-57. [Medline].

8. Chen QY, Huang W, She JX, et al. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab. Sep 1999;84(9):3182-6. [Medline]. [Full Text].

9. Chen QY, Nadell D, Zhang XY, et al. The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans. J Clin Endocrinol Metab. Apr 2000;85(4):1545-9. [Medline]. [Full Text].

10. Das PK, Wherrett D, Dror Y. Remission of aplastic anemia induced by treatment for Graves disease in a pediatric patient. Pediatr Blood Cancer. 2006;[Medline].

11. Durairaj VD, Bartley GB, Garrity JA. Clinical features and treatment of graves ophthalmopathy in pediatric patients. Ophthal Plast Reconstr Surg. 2006;22:7-12. [Medline].

12. Garel C, Leger J. Thyroid imaging in children. Endocr Dev. 2007;10:43-61. [Medline].

13. Golomb MR, Biller J, Smith JL, et al. A 10-year-old girl with coexistent moyamoya disease and Graves' disease. J Child Neurol. Jul 2005;20(7):620-4. [Medline].

14. Graves PN, Davies TF. New insights into the thyroid-stimulating hormone receptor. The major antigen of Graves' disease. Endocrinol Metab Clin North Am. Jun 2000;29(2):267-86, vi. [Medline].

15. Lazar L, Kalter-Leibovici O, Pertzelan A, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. Oct 2000;85(10):3678-82. [Medline]. [Full Text].

16. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long-term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. Jun 1987;64(6):1241-5. [Medline].

17. Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?. Eur J Nucl Med Mol Imaging. 2007;34:1504-9. [Medline].

18. Mittra ES, Niederkohr RD, Rodriguez C, El-Maghraby T, McDougall IR. Uncommon causes of thyrotoxicosis. J Nucl Med. 2008;49:265-78. [Medline].

19. Mora S, Weber G, Marenzi K, et al. Longitudinal changes of bone density and bone resorption in hyperthyroid girls during treatment. J Bone Miner Res. Nov 1999;14(11):1971-7. [Medline].

20. Moriyama T, Yamashita H, Noguchi S, et al. Intraoperative parathyroid hormone assay in patients with Graves' disease for prediction of postoperative tetany. World J Surg. Oct 2005;29(10):1282-7. [Medline].

21. Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr. 2005;146:533-536. [Medline].

22. Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, et al. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. Nov 1994;131(5):467-73. [Medline].

23. Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children: thirty years' experience. Acta Paediatr. 1999;88:937-41. [Medline].

24. Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. Nov 1998;83(11):3767-76. [Medline]. [Full Text].

25. Ross DS, Daniels GH, De Stefano P, et al. Use of adjunctive potassium iodide after radioactive iodine (131-I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983;57(2):250-3. [Medline].

26. Sipe WE, Su M, Posselt A, et al. Propylthiouracil-associated liver failure presenting as probable autoimmune hepatitis in a child with Graves's disease. Pediatr Transplant. 2006;10:525-528. [Medline].

27. Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. Jun 2005;18(6):597-602. [Medline].

28. Sugino K, Ito K, Mimura T, et al. Surgical treatment of Graves' disease in children. Thyroid. 2004;14:447-452. [Medline].

29. Tan SH, Lee BW, Wong HB, Uma R. Relapse markers in childhood thyrotoxicosis. Clin Pediatr (Phila). Mar 1987;26(3):136-9. [Medline].

30. Tellez M, Cooper J, Edmonds C. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf). 1992;36:291-4. [Medline].

31. Ward L, Huot C, Lambert R, et al. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine. Clin Invest Med. Aug 1999;22(4):132-9. [Medline].

32. Wiersinga WM. Thyroid associated ophthalmopathy: pediatric and endocrine aspects. Pediatr Endocrinol Rev. 2004;1:513-517. [Medline].

33. Wood LC. Support groups for patients with Graves' disease and other thyroid conditions. Endocrinol Metab Clin North Am. 1998;27:101-7. [Medline].

34. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am. Mar 1998;27(1):109-26. [Medline].

Further Reading

Keywords

Graves disease, Graves's disease, hyperthyroidism, thyrotoxicosis, von Basedow disease, thyroid-stimulating immunoglobulin, TSI, thyroxine, T4, triiodothyronine, T3, transient neonatal Graves thyrotoxicosis, insomnia, attention deficit hyperactivity disorder, ADHD, heat intolerance, muscle wasting, decreased bone density, hypercalcuria, hyposthenuria, nocturnal enuresis, thyroid storm, exophthalmos, enlarged thyroid, attention deficit disorder, ADD, mitral valve prolapse, atrial fibrillation, hypokalemia, acanthosis nigricans, café au lait spots, McCune-Albright syndrome

Contributor Information and Disclosures

Author

Robert J Ferry Jr, MD, Chief, Division of Pediatric Endocrinology and Metabolism, Le Bonheur Children's Medical Center, University of Tennessee Health Science Center at Memphis, and St Jude Children's Research Hospital; Field Surgeon (Medical Corps), 162nd Area Support Medical Company, Army National Guard
Robert J Ferry Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, Society for Pediatric Research, and Texas Pediatric Society
Disclosure: Nutropin Speakers Bureau Honoraria Speaking and teaching; Genotropin Speakers Bureau Honoraria Speaking and teaching; Eli Lilly & Co. Grant/research funds Independent contractor; MacroGenics, Inc. Grant/research funds Independent contractor; Ipsen, S.A. (formerly Tercica, Inc.) Grant/research funds Independent contractor

Coauthor(s)

Lynne Lipton Levitsky, MD, Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor, Department of Pediatrics, Harvard University Medical School
Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds PI, also occasional consultant

Medical Editor

Thomas A Wilson, MD, Professor of Clinical Pediatrics, Department of Pediatrics; Director of Pediatric Endocrinology, Division of Pediatric Endocrinology, Department of Pediatrics, State University of New York at Stony Brook
Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London), Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece
George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting